Junshi Biosciences, a China-based biopharmaceutical company, and Merck have entered a collaboration for a clinical trial program to investigate the efficacy and safety of anti-PD-1 mAb toripalimab (TUOYI) in combination with Cetuximab (Erbitux) as a treatment for recurrent and/or metastatic squamous cell carcinomas of the head and neck (R/M SCCHN) in China. Head and neck cancer is one of the most common cancer types in China, with more than 135,000 new cases each year and about 70,000 deaths....